Topoisomerase 2β: A Promising Molecular Target for Primary Prevention of Anthracycline‐Induced Cardiotoxicity

@article{Vejpongsa2014Topoisomerase2A,
  title={Topoisomerase 2$\beta$: A Promising Molecular Target for Primary Prevention of Anthracycline‐Induced Cardiotoxicity},
  author={P. Vejpongsa and Eth Yeh},
  journal={Clinical Pharmacology \& Therapeutics},
  year={2014},
  volume={95}
}
Anthracyclines are powerful chemotherapy agents that are still widely used today. However, their clinical use is limited by the development of dose‐dependent cardiotoxicity. Recently, we showed that topoisomerase 2β (Top2β) is required for anthracycline to induce DNA double‐strand breaks and changes in the transcriptome, leading to mitochondrial dysfunction and generation of reactive oxygen species. Furthermore, deleting Top2β from cardiomyocytes prevented the development of anthracycline… Expand
Statins in anthracycline-induced cardiotoxicity: Rac and Rho, and the heartbreakers
Cardiotoxicity of anthracycline therapy: current perspectives
Influence of PARP-1 inhibition in the cardiotoxicity of the topoisomerase 2 inhibitors doxorubicin and mitoxantrone.
  • R. Damiani, D. Moura, +4 authors J. Saffi
  • Chemistry, Medicine
  • Toxicology in vitro : an international journal published in association with BIBRA
  • 2018
Prevention of anthracycline-induced cardiotoxicity: challenges and opportunities.
Pathophysiology and preventive strategies of anthracycline-induced cardiotoxicity
Recent progress in doxorubicin-induced cardiotoxicity and protective potential of natural products.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 84 REFERENCES
Roles of DNA topoisomerase II isozymes in chemotherapy and secondary malignancies
NK314, a Topoisomerase II Inhibitor That Specifically Targets the α Isoform*
Identification of the molecular basis of doxorubicin-induced cardiotoxicity
Topoisomerase II beta expression level correlates with doxorubicin-induced apoptosis in peripheral blood cells
...
1
2
3
4
5
...